Cellular and humoral immunity to SARS‐CoV‐2 infection in multiple sclerosis patients on ocrelizumab and other disease‐modifying therapies: a multi‐ethnic …

I Kister, Y Patskovsky, R Curtin, J Pei… - Annals of …, 2022 - Wiley Online Library
Objective The objective of this study was to determine the impact of multiple sclerosis (MS)
disease‐modifying therapies (DMTs) on the development of cellular and humoral immunity …
被引用次数：22 相关文章
[HTML] europepmc.org

[HTML][HTML] Cellular and humoral immunity to SARS-CoV-2 infection in multiple sclerosis patients on ocrelizumab and other disease-modifying therapies: a multi-ethnic …

I Kister, Y Patskovsky, R Curtin, J Pei, K Perdomo… - 2022 - europepmc.org
Objective To determine the impact of MS disease-modifying therapies (DMTs) on the
development of cellular and humoral immunity to SARS-CoV-2 infection. Methods MS …
[PDF] archive.org

[PDF][PDF] Cellular and humoral immunity to SARS-CoV-2 infection in multiple sclerosis patients on ocrelizumab and other disease-modifying therapies: a multi-ethnic …

MI Voloshyna, AR Cornelius, Y Velmurugu, S Nyovanie… - scholar.archive.org
Objective: To determine the impact of MS disease-modifying therapies (DMTs) on the
development of cellular and humoral immunity to SARS-CoV-2 infection. Methods: MS …

Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic …

I Kister, Y Patskovsky, R Curtin, J Pei… - Annals of …, 2022 - pubmed.ncbi.nlm.nih.gov
Objective The objective of this study was to determine the impact of multiple sclerosis (MS)
disease-modifying therapies (DMTs) on the development of cellular and humoral immunity …
[PDF] scienceopen.com

[PDF][PDF] Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic …

I Kister, Y Patskovsky, R Curtin, J Pei, K Perdomo… - 2022 - scienceopen.com
Objective: The objective of this study was to determine the impact of multiple sclerosis (MS)
disease-modifying therapies (DMTs) on the development of cellular and humoral immunity …
[PDF] academia.edu

[PDF][PDF] Cellular and humoral immunity to SARS-CoV-2 infection in multiple sclerosis patients on ocrelizumab and other disease-modifying therapies: a multi-ethnic …

MI Voloshyna, AR Cornelius, Y Velmurugu, S Nyovanie… - academia.edu
Objective: To determine the impact of MS disease-modifying therapies (DMTs) on the
development of cellular and humoral immunity to SARS-CoV-2 infection. Methods: MS …
[HTML] nih.gov

[HTML][HTML] Cellular and Humoral Immunity to SARS‐CoV‐2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease‐Modifying Therapies: A Multi …

I Kister, Y Patskovsky, R Curtin, J Pei… - Annals of …, 2022 - ncbi.nlm.nih.gov
Objective The objective of this study was to determine the impact of multiple sclerosis (MS)
disease‐modifying therapies (DMTs) on the development of cellular and humoral immunity …

Cellular and humoral immunity to SARS-CoV-2 infection in multiple sclerosis patients on ocrelizumab and other disease-modifying therapies: a multi-ethnic …

I Kister, Y Patskovsky, R Curtin, J Pei, K Perdomo… - 2022 - cabidigitallibrary.org
Objective: The objective of this study was to determine the impact of multiple sclerosis (MS)
disease-modifying therapies (DMTs) on the development of cellular and humoral immunity …

Cellular and Humoral Immunity to SARS‐CoV‐2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease‐Modifying Therapies: A Multi‐Ethnic …

I Kister, Y Patskovsky, R Curtin, J Pei… - Annals of …, 2022 - search.ebscohost.com
Objective: The objective of this study was to determine the impact of multiple sclerosis (MS)
disease‐modifying therapies (DMTs) on the development of cellular and humoral immunity …

Cellular and humoral immunity to SARS-CoV-2 infection in multiple sclerosis patients on ocrelizumab and other disease-modifying therapies: a multi-ethnic …

I Kister, Y Patskovsky, R Curtin, J Pei, K Perdomo… - medRxiv, 2022 - medrxiv.org
Objective To determine the impact of MS disease-modifying therapies (DMTs) on the
development of cellular and humoral immunity to SARS-CoV-2 infection. Methods MS …